摘要
多囊卵巢综合征（PCOS）是育龄女性常见的内分泌代谢紊乱综合征，常伴有肥胖、高雄激素血症、高胰岛素血症及胰岛素抵抗（IR）等代谢综合征（MS）的表现。目前新的观点认为氧化应激是PCOS患者发病的一个潜在诱发因素。胰高血糖素样肽-1（GLP-1）受体激动剂及类似物作为治疗2型糖尿病（T2DM）的新型药物，能够减重，改善IR、抗氧化应激及降低炎性因子的表达，因而GLP-1受体激动剂及类似物在PCOS患者的临床应用中越来越广泛。笔者就GLP-1受体激动剂及类似物治疗PCOS的近期进展作一综述。
Polycystic ovary syndrome （PCOS） is a common endocrine metabolic disorder of repro- ductive age women, often accompanied by obesity, hyperandrogenism, hyperinsulinemia, insulin resistance （IR）, and other metabolic syndrome （MS）. Oxidative stress （OS） is considered as a potential inducing factor in the pathogenesis of PCOS at present. Glucagon-like peptide-1 （ glp-1 ） receptor agonist and ana- logues as new therapeutic agents in the treatment of type 2 diabetes mellitus （T2DM）, can lose weight, im- prove IR, resist OS and reduce the expression of inflammatory cytokines, thus they have been widely used in the clinical application of patients with PCOS. The author reviews the latest advances of glucagon-like pep- tide-1 on polycystic ovary syndrome.
出处
《中国医师杂志》
CAS
2016年第12期1908-1910,共3页
Journal of Chinese Physician
